Thalassemias: from gene to therapy

Area of Science:

• Hematology
• Genetics
• Molecular Biology

Background:

• Thalassemias are the most prevalent global genetic disorders, stemming from deficient hemoglobin chain synthesis.
• This deficiency causes red blood cell destruction and anemia, with diverse genetic causes and clinical presentations.
• Geographic distribution varies, with alpha and beta thalassemias common in Mediterranean and Asian regions.

Purpose of the Study:

• To provide a comprehensive overview of thalassemias.
• To discuss historical, geographic, genetic, and molecular aspects.
• To explore current and emerging therapeutic strategies.

Main Methods:

• Literature review and synthesis of existing research on thalassemia.
• Analysis of molecular and epigenetic regulation of globin gene expression.
• Evaluation of conventional and novel treatment modalities.

Main Results:

• Thalassemias result from diverse genetic defects, leading to varied clinical severity.
• Globin gene expression is regulated by complex molecular and epigenetic pathways.
• Conventional treatments like transfusions and chelation have limitations.

Conclusions:

• Gene therapy and gene editing represent significant advancements for thalassemia treatment.
• These novel approaches hold promise for curative outcomes.
• Ongoing research addresses challenges in developing effective and accessible curative therapies.